Fig. 7.

Effect of chronic inhibition of CXCR1/2 by Reparixin on body weight, activity level or disc height in SPARC-null or WT mice. Mice were treated with Reparixin (20 mg/kg, i.p.) or vehicle 3 times/week for 8 weeks. A) No statistical differences between either strain or treatment were observed in body weight, although the WT mice tended to be heavier than SPARC-null. B) No strain or treatment effects were observed in overall distance travelled in an open field at baseline or on non-treatment days during weeks 3 or 7. C) Following 8 weeks of chronic CXCR1/2 inhibition lumbar spines were imaged with X-ray and disc height index was determined. While L2/3 and L3/4 disc height was reduced in SPARC-null mice compared to WT, reparixin had no effect in either strain. Data is presented as mean ± SEM, n = 9–10 per SPARC-null groups, n = 4–6 per WT groups. Data was analyzed by two-way repeated measures ANOVA with Tukey's post hoc test post-hoc test. * = p < 0.05, ** = p < 0.01.